CA2930055C — Pharmaceutical dosage forms comprising protein kinase inhibitor
Assigned to Novartis AG · Expires 2023-07-04 · 3y expired
What this patent protects
The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1 -{6-[4-(4-ethyl-piperazin-1 -yl)- phenylamino]-pyrimidin-4-yl}-1 -methyl-urea or any pharmaceutically acceptable salt thereof. It further relat…
USPTO Abstract
The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1 -{6-[4-(4-ethyl-piperazin-1 -yl)- phenylamino]-pyrimidin-4-yl}-1 -methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.